Price Blame Game
Abstract
Supporters of plans to allow the reimportation of drugs to the United States from other countries seized on the Medicare card controversy to exert pressure on lawmakers to legalize the practice. The Food and Drug Administration held several forums this spring to debate the safety of reimported drugs, while Congressional hearings focused on whether the United States unfairly shoulders the worldwide costs of drug research and development. At a joint hearing of the Health Care and Foreign Trade...